Assessment of an Innovative Voluntary Substance Abuse Treatment Program Designed to Replace Compulsory Drug Detention Centers in Malaysia
Overview
Authors
Affiliations
Background: As part of an ongoing initiative by the Malaysian government to implement alternative approaches to involuntary detention of people who use drugs, the National Anti-Drug Agency has created new voluntary drug treatment programs known as Cure and Care (C&C) Centers that provide free access to addiction treatment services, including methadone maintenance therapy, integrated with social and health services.
Objectives: We evaluated early treatment outcomes and client satisfaction among patients accessing C&C treatment and ancillary services at Malaysia's second C&C Center located in Kota Bharu, Kelantan.
Methods: In June-July 2012, a cross-sectional convenience survey of 96 C&C inpatients and outpatients who entered treatment >30 days previously was conducted to assess drug use, criminal justice experience, medical co-morbidities, motivation for seeking treatment, and attitudes towards the C&C. Drug use was compared for the 30-day-period before C&C entry and the 30-day-period before the interview.
Results: Self-reported drug use levels decreased significantly among both inpatient and outpatient clients after enrolling in C&C treatment. Higher levels of past drug use, lower levels of social support, and more severe mental health issues were reported by participants who were previously imprisoned. Self-reported satisfaction with C&C treatment services was high. Conclusions/Importance: Preliminary evidence of reduced drug use and high levels of client satisfaction among C&C clients provide support for Malaysia's ongoing transition from compulsory drug detention centers (CDDCs) to these voluntary drug treatment centers. If C&C centers are successful, Malaysia plans to gradually transition away from CDDCs entirely.
Shaari A, Waller B Soc Work Groups. 2023; 46(1):51-67.
PMID: 36969301 PMC: 10035536. DOI: 10.1080/01609513.2022.2057393.
Huang K, Yu C, Chen X, Hao Y, Ding Y, Wu Z Front Psychiatry. 2021; 12:613665.
PMID: 34512405 PMC: 8429503. DOI: 10.3389/fpsyt.2021.613665.
Wegman M, Altice F, Kaur S, Rajandaran V, Osornprasop S, Wilson D Lancet Glob Health. 2016; 5(2):e198-e207.
PMID: 27964869 PMC: 5657487. DOI: 10.1016/S2214-109X(16)30303-5.
Culbert G, Pillai V, Bick J, Al-Darraji H, Wickersham J, Wegman M J Neuroimmune Pharmacol. 2016; 11(3):446-55.
PMID: 27216260 PMC: 5118227. DOI: 10.1007/s11481-016-9676-7.
Wickersham J, Loeliger K, Marcus R, Pillai V, Kamarulzaman A, Altice F Am J Drug Alcohol Abuse. 2015; 42(1):98-110.
PMID: 26636885 PMC: 4837957. DOI: 10.3109/00952990.2015.1101467.